On January 5, 2026, Geron Corporation entered into that certain first amendment to loan agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a 'Lender'), whic…
On January 5, 2026, Geron Corporation entered into that certain first amendment to loan agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a 'Lender'), whic…
Upon the effective date of termination of the license and collaboration agreement, or the Prior Collaboration Agreement, with Janssen Biotech, Inc., or Janssen, on September 28, 2018, we regained glo…
On January 5, 2026, Geron Corporation entered into that certain first amendment to loan agreement with BioPharma Credit Investments V (Master) LP and BPCR Limited Partnership (each, a 'Lender'), whic…
Geron Corporation Customers
No clients on recordNo downstream customers found in our database for Geron Corporation.
Geron Corporation Debt Obligations
Instrument
Description
Confidence
Evidence
GERN-DEBT-9764
Warrants outstanding: 1619275
90%
xbrl warrant detail from xbrl 2025-12-31.
GERN-DEBT-9765
Xbrl Convertible
90%
xbrl convertible detail from xbrl 2015-12-31.
GERN-DEBT
Debt stack $122.1M
90%
Market cache reports total debt of $122.1M.
Geron Corporation Acquisitions
No acquisitions on recordNo completed or pending acquisitions found in our database for Geron Corporation.
Geron Corporation Ownership
Holder
Name
Confidence
Evidence
GERN-OWNER-RA-CAPITAL-MANAGEMENT-L-P
RA CAPITAL MANAGEMENT, L.P.
90%
13F overlay lists RA CAPITAL MANAGEMENT, L.P. as top holder; 256 tracked holders.
